You must log in to view this page.

Viridian Therapeutics Inc. – Filings and Transcripts

NASDAQ: VRDN
Share price (11/6/26): $28.49
Market cap (11/6/26): $3.235 billion

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 09/30/26 Q3

ended 06/30/26 Q2

ended 03/31/26 Q1

ended 12/31/25 FY 2025

ended 09/30/25 Q3

Prospectuses and Registrations Filter

Prospectus supplement for primary offering

Prospectus supplement for primary offering

Free writing prospectus

Free writing prospectus

Prospectus supplement for primary offering

Ownership Filter

Tousignant Jennifer

Point72 Asset Management, L.P.

Tousignant Jennifer

Tripuraneni Radhika

Kynam Capital Management, LP

News Filter

Reports Third Quarter 2026 Financial Results and Highlights Recent Business Progress

Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results

Announces U.S. FDA Approval and Launch of Lumvoa™ (Veligrotug-Vvze) for the Treatment of Thyroid Eye Disease

Shareholder Vote Results

Termination of Material Definitive Agreement

Proxies Filter

Additional info about upcoming vote

Definitive proxy

Additional info about upcoming vote

Definitive proxy

Additional info about upcoming vote

Other Filter

Statement of eligibility as a trustee

Scanned paper annual report submission

Scanned paper annual report submission

Scanned paper annual report submission

Scanned paper annual report submission